New Bridge Bio to present updated Phase IIa clinical data for dual-target eye drug VIS-101

prnasia.com (Chinese)

New Bridge Bio will release Phase IIa clinical data for its dual-target eye drug VIS-101 on March 9. The drug targets VEGF-A and ANG2, aiming for more effective and longer-lasting treatments for wet AMD and other retinal conditions. VIS-101 is expected to begin Phase III trials in 2026, with potential to become a new standard of care.


With a significance score of 1.5, this news ranks in the top 38% of today's 32101 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


New Bridge Bio to present updated Phase IIa clinical data for dual-target eye drug VIS-101 | News Minimalist